NCT07504328

Brief Summary

Robson Classification System Monitoring and Auditing Caesrean Section Rates

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
9mo left

Started Feb 2026

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress21%
Feb 2026Feb 2027

Study Start

First participant enrolled

February 1, 2026

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

March 18, 2026

Completed
13 days until next milestone

First Posted

Study publicly available on registry

March 31, 2026

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2027

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2027

Last Updated

March 31, 2026

Status Verified

March 1, 2026

Enrollment Period

11 months

First QC Date

March 18, 2026

Last Update Submit

March 25, 2026

Conditions

Caesrean Section RatesRobson Classification

Keywords

Robson ClassificationCaesrean Section Rates

Outcome Measures

Primary Outcomes (1)

  • Change in overall Caesarean section rate

    All eligible deliveries during the study period will be included (total coverage sampling). Collection of baseline data on mode of delivery. Calculation of CS rate and indications. Classification of women retrospectively into Robson groups. Monthly audit meetings to discuss CS indications per Robson group. Data Collection Data will be collected using a structured sheet including: Maternal age Parity Gestational age Onset of labor Fetal presentation Number of fetuses Mode of delivery Indication of CS Robson group Maternal outcome Neonatal outcome

    until 1/february/2027

Secondary Outcomes (1)

  • Cs rate in each Robson group. Change in primary Cs rate. Change in repeat Cs rate. Matenal morbidity. Neonatal outcomes(Apgar,NICU admission)

    until 1/february/2027

Study Arms (1)

Pregnant Women delivering at>28weeks gestaion

Pregnant Women delivering at\>28weeks gestaion (interuterine fetal demises before admission are excluded)

Other: just monitoring and auditing ,so there is no intevention

Interventions

just monitoring and auditing ,so there is no inteventionOTHER

just monitoring and auditing ,so there is no intevention

Pregnant Women delivering at>28weeks gestaion

Eligibility Criteria

Sexfemale(Gender-based eligibility)
Gender Eligibility Detailspregnant women at \>=28 weeks gestaion age.
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

pregnant women at \>=28 weeks gestaion age.

You may qualify if:

  • All pregnant women delivering at ≥ 28 weeks gestation.
  • Singleton or multiple pregnancy.
  • Cephalic, Breech, or transverse lie.

You may not qualify if:

  • Gestational age \< 28 weeks.
  • Intrauterine fetal demises before admission

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sohag University

Sohag, 82524, Egypt

Location

Study Officials

  • Ahmed Abd El Raheem Ahmed

    Sohag University

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Target Duration
1 Day
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator (resident doctor)

Study Record Dates

First Submitted

March 18, 2026

First Posted

March 31, 2026

Study Start

February 1, 2026

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

February 1, 2027

Last Updated

March 31, 2026

Record last verified: 2026-03

Locations

EG(1)